


PRODUCT INFORMATION



FLT3 Inhibitor III

Item No. 21193

CAS Registry No.: 852045-46-6
Formal Name: 5-phenyl-N-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-thiazolamine
Synonym: Fms-like Tyrosine Kinase Inhibitor III
MF: C₂₁H₂₃N₃OS
FW: 365.5
Purity: ≥98%
UV/Vis.: λ_{max}: 335 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

FLT3 Inhibitor III is supplied as a crystalline solid. A stock solution may be made by dissolving the FLT3 inhibitor III in the solvent of choice. FLT3 Inhibitor III is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of FLT3 inhibitor III in ethanol is approximately 20 mg/ml and approximately 30 mg/ml in DMSO and DMF.

FLT3 Inhibitor III is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, FLT3 inhibitor III should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. FLT3 Inhibitor III has a solubility of approximately 0.25 mg/ml in a 1:4 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

FLT3 Inhibitor III is a potent inhibitor of Fms-like tyrosine kinase 3 (FLT3; IC₅₀ = 50 nM).¹ It shows high selectivity for FLT3 over a panel of 300 other kinases.^{1,2} FLT3 Inhibitor III blocks FLT-dependent cell proliferation in a dose-dependent manner.¹ FLT3 Inhibitor III has been used to study signaling through FLT3 and FLT3 with internal tandem duplications (FLT3-ITD) in cells.³⁻⁵

References

1. Furet, P., Bold, G., Meyer, T., *et al.* Aromatic interactions with phenylalanine 691 and cysteine 828: A concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents. *J. Med. Chem.* **49(15)**, 4451-4454 (2006).
2. Anastassiadis, T., Deacon, S.W., Devarajan, K., *et al.* Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. *Nat. Biotechnol.* **29(11)**, 1039-1045 (2011).
3. Bertoli, S., Boutzen, H., David, L.E., *et al.* CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia. *Oncotarget* **6(35)**, 38061-38078 (2015).
4. Jiang, J., and Griffin, J.D. Wnt/β-catenin pathway modulates the sensitivity of the mutant FLT3 receptor kinase inhibitors in a GSK-3β dependent manner. *Genes Cancer* **1(2)**, 164-176 (2010).
5. Kang, Y., Tiziani, S., Park, G., *et al.* Cellular protection using Flt3 and PI3Ka inhibitors demonstrates multiple mechanisms of oxidative glutamate toxicity. *Nat. Commun.* **5**, 3672 (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/24/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM